Search Results - "TAYLOR, D. O"

Correlation of Donor‐Specific Antibodies, Complement and Its Regulators with Graft Dysfunction in Cardiac Antibody‐Mediated Rejection by Tan, C. D., Sokos, G. G., Pidwell, D. J., Smedira, N. G., Gonzalez‐Stawinski, G. V., Taylor, D. O., Starling, R. C., Rodriguez, E. R.

“…Antibody‐mediated rejection (AMR) is an immunopathologic process in which activation of complement often results in allograft injury. This study correlates C4d…”
Get full text

Progressive Multifocal Leukoencephalopathy in a Heart Transplant Recipient Following Rituximab Therapy for Antibody‐Mediated Rejection by Loyaga‐Rendon, R. Y., Taylor, D. O., Koval, C. E.

“…We report the case of a male heart transplant recipient who developed acute antibody‐mediated rejection and was treated with 5 weeks of a rituximab‐containing…”
Get full text

Heart Retransplantation by Johnson, M. R., Aaronson, K. D., Canter, C. E., Kirklin, J. K., Mancini, D. M., Mehra, M. R., Radovancevic, B., Taylor, D. O., Webber, S. A.

“…Retransplants comprise only a small minority (3–4%) of heart transplants, however outcome following retransplantation is compromised. Risk factors for a poor…”
Get full text

Changes in Donor Heart Allocation in the United States Without Fundamental Changes in the System: Rearranging Deck Chairs and Elephants in the Room by Barr, M. L., Taylor, D. O.

“…Meaningful changes in US heart allocation require a realistic, transparent, and candid discussion of fundamental and often ignored issues that exist in both…”
Get full text

Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression by Yamani, M.H., Taylor, D.O., Haire, C., Smedira, N., Starling, R.C.

“…:  Background:  The AlloMap gene expression test is used for the non‐invasive detection of rejection. However, the impact of early post‐transplant ischemic…”
Get full text

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus by Taylor, D O, Barr, M L, Radovancevic, B, Renlund, D G, Mentzer, Jr, R M, Smart, F W, Tolman, D E, Frazier, O H, Young, J B, VanVeldhuisen, P

“…Tacrolimus-based immunosuppression seems safe and effective in liver and kidney transplantation. To assess the safety and efficacy of tacrolimus (TAC)-based…”
Get more information

Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study by Olsen, Stephanie L., Gilbert, Edward M., Renlund, Dale G., Taylor, David O., Yanowitz, Frank D., Bristow, Michael R.

“…This study assessed the safety and efficacy of carvedilol in patients with heart failure caused by idiopathic or ischemic cardiomyopathy. Carvedilol is a…”
Get full text

The Effect of Recipient Hepatitis C Virus Infection on Outcomes Following Heart Transplantation by Shafii, A.E, Su, J.W, Smedira, N.G, Navia, J.L, Taylor, D.O, Starling, R.C, Gonzalez-Stawinski, G

“…Abstract Background Insufficient data exist on the clinical course of hepatitis C virus (HCV) infection in heart transplant (HT) recipients. Our study reports…”
Get full text

Near-surface soils: discrete element modeling of self-supported unconfined drained sand specimens by Allen, J. B., Taylor, O. -D. S.

“…Recent findings demonstrate that traditional equations governing near surface, low confinement, soil mechanics may not accurately represent changes in soil…”
Get full text

Survival Beyond 10 Years Following Heart Transplantation: The Cleveland Clinic Foundation Experience by Ozduran, V., Yamani, M.H., Chuang, H.-H., Sipahi, I., Cook, D.J., Sendrey, D., Tong, L., Hobbs, R., Rincon, G., Bott-Silverman, C., James, K., Taylor, D.O., Young, J.B., Navia, J., Banbury, M., Smedira, N., Starling, R.C.

“…Long-term survival after heart transplantation is a desirable although challenging goal. We analyzed clinical outcomes in the cohort of 170 patients who have…”
Get full text

Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection by Taylor, D O, Yowell, R L, Kfoury, A G, Hammond, E H, Renlund, D G

Get more information

Inflammatory myocardial diseases and cardiomyopathies by Pisani, B, Taylor, D O, Mason, J W

“…Inflammatory myocardial disease has been associated with a variety of infectious and noninfectious etiologies. It is associated with the development of dilated…”
Get more information

Attrition From Heart Transplant Waiting List for Patients on Ventricular Assist Devices Is Not Affected by Desensitization Strategies by Gonzalez-Stawinski, G.V, Cook, D.J, Smedira, N.G, Navia, J.L, Taylor, D.O, Yamani, M.H, Hoercher, K, Starling, R.C, Banbury, M.K

“…Abstract Background Ventricular assist device (VAD) patients, who are commonly sensitized, can be successfully transplanted using strategies aimed at…”
Get full text

Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation by Taylor, D O, Ensley, R D, Olsen, S L, Dunn, D, Renlund, D G

“…Mycophenolate mofetil (formerly known as RS-61443) is a morpholinoethyl ester of mycophenolic acid. Mycophenolic acid is a unique immunosuppressive agent…”
Get more information

A novel neoplastic primary tumor-derived human prostate epithelial cell line by Ko, Daejin, Gu, Yongpeng, Yasunaga, Yutaka, Nakamura, Keiichiro, Srivastava, Shiv, Moul, Judd W, Sesterhenn, Isabell A, McLeod, David G, Arnstein, Paul, Taylor, D O, Hukku, Bharati, Rhim, Johng S

“…Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro models of prostate tumors representing…”
Get more information

Immunosuppression for cardiac transplantation—the past, present and future by O'Neill, J.O, Taylor, D.O, Starling, R.C

“…The field of cardiac transplant immunosuppression is rapidly developing and has evolved over the past 35 years. Anecdote, experience and registry based…”
Get full text

Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy by Taylor, D O, Bristow, M R, O'Connell, J B, Price, G D, Hammond, E H, Doty, D B, Karwande, S V, Gay, Jr, W A, Jones, K W, Lappé, D, Renlund, D G

“…Short-term studies suggest that cardiac transplant immunosuppression without maintenance corticosteroids is feasible in selected patients. However, concern…”
Get more information

Immunosuppression and Heart Transplantation: How Do We Define Success? by Baran, D. A., Taylor, D. O., Kobashigawa, J. A.

“…How do we balance the trade‐offs between reduced rates of allograft rejection and other morbidities such as renal dysfunction, myelosuppression and…”
Get full text

Exercise capacity after heart transplantation: influence of donor and recipient characteristics by Renlund, D G, Taylor, D O, Ensley, R D, O'Connell, J B, Gilbert, E M, Bristow, M R, Ma, H, Yanowitz, F G

“…For incompletely understood reasons, cardiac transplant recipients achieve only 60% to 70% of predicted values for maximal exercise capacity. The objective was…”
Get more information

Immunosuppressive therapy, management, and outcome of heart transplant recipients during pregnancy by Wagoner, L E, Taylor, D O, Olsen, S L, Price, Sr, G D, Rasmussen, L G, Larsen, C B, Scott, J R, Renlund, D G

“…To evaluate challenges facing heart transplant recipients who become pregnant, we surveyed 194 heart transplantation centers and reviewed the literature…”
Get more information